Cat. No.: HY-14754

Salirasib

Name: Salirasib
Brand: MedChemExpress
SKU: HY-14754
Price: 40.00 USD
Availability: InStock
Rating: 5 (16 reviews)

(Synonyms: S-Farnesylthiosalicylic acid; Farnesyl Thiosalicylic Acid; FTS)

16 Cited Publications

Customer Review

Based on 16 publication(s) in Google Scholar

Salirasib is a Ras inhibitor that inhibits specifically both oncogenically activated Ras and growth factor receptor-mediated Ras activation, resulting in the inhibition of Ras-dependent tumor growth.

For research use only. We do not sell to patients.

Purity : 99.04%
CAS No.: 162520-00-5
Formula: C₂₂H₃₀O₂S
Molecular Weight:358.54

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Salirasib Chemical Structure

CAS No.: 162520-00-5

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (16)
Solvent & Solubility
- In Vitro
- In Vivo
Protocols (4)
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target

Ki: 2.6 μM (PPMTase)

All Ras Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	GI₅₀	34 μM Compound: 12	Antiproliferative activity against human A549 cells assessed as inhibition of culture growth incubated for 48 hrs by SRB assay Antiproliferative activity against human A549 cells assessed as inhibition of culture growth incubated for 48 hrs by SRB assay	[PMID: 37531922]
Bel-7402	IC₅₀	76.13 μM Compound: 1, FTS, S-trans,trans-FTS, Salirasib	Cytotoxicity against human Bel7402 cells after 48 hrs by MTT based ELISA Cytotoxicity against human Bel7402 cells after 48 hrs by MTT based ELISA	[PMID: 21504204]
BXPC-3	EC₅₀	>20 μM Compound: FTS, Salirasib	Cytotoxicity against human BxPC3 cells after 48 hrs by fluorescence assay Cytotoxicity against human BxPC3 cells after 48 hrs by fluorescence assay	[PMID: 24852279]
CHO	EC₅₀	5 μM Compound: 10	Agonist activity at human TRPA1 channel expressed in CHO cells assessed as increase in intracellular calcium levels Agonist activity at human TRPA1 channel expressed in CHO cells assessed as increase in intracellular calcium levels	[PMID: 20356305]
EJ	EC₅₀	7.5 μM Compound: 2	Effective concentration required for 50% inhibition of growth of human Ha-ras-transformed rat 1 (EJ)cells Effective concentration required for 50% inhibition of growth of human Ha-ras-transformed rat 1 (EJ)cells	[PMID: 7731012]
EJ	IC₅₀	47.6 μM Compound: FTS	Cytotoxicity against human EJ cells after 48 hrs by MTT assay Cytotoxicity against human EJ cells after 48 hrs by MTT assay	[PMID: 24300920]
EJ	IC₅₀	48.6 μM Compound: Farnesyl Thiosalicylic acid	Cytotoxicity against human EJ cells assessed as inhibition of cell growth by MTT assay Cytotoxicity against human EJ cells assessed as inhibition of cell growth by MTT assay	[PMID: 32791404]
HBL-100	GI₅₀	22 μM Compound: 12	Antiproliferative activity against human HBL-100 cells assessed as inhibition of culture growth incubated for 48 hrs by SRB assay Antiproliferative activity against human HBL-100 cells assessed as inhibition of culture growth incubated for 48 hrs by SRB assay	[PMID: 37531922]
HEK293	EC₅₀	0.8 μM Compound: FTS	Agonist activity at human TRPA1 expressed in HEK293 cells assessed as increase in calcium influx by Fluo-4-AM dye based fluorescence assay Agonist activity at human TRPA1 expressed in HEK293 cells assessed as increase in calcium influx by Fluo-4-AM dye based fluorescence assay	[PMID: 30878828]
HEK293	EC₅₀	7 μM Compound: FTS	Agonist activity at human TRPA1 expressed in HEK293 cells assessed as increase in calcium influx by Fluo-3/acetoxymethyl ester dye based FLIPR analysis Agonist activity at human TRPA1 expressed in HEK293 cells assessed as increase in calcium influx by Fluo-3/acetoxymethyl ester dye based FLIPR analysis	[PMID: 30878828]
HeLa	GI₅₀	34 μM Compound: 12	Antiproliferative activity against human HeLa cells assessed as inhibition of culture growth incubated for 48 hrs by SRB assay Antiproliferative activity against human HeLa cells assessed as inhibition of culture growth incubated for 48 hrs by SRB assay	[PMID: 37531922]
Hep 3B2	IC₅₀	63.75 μM Compound: 1, FTS, S-trans,trans-FTS, Salirasib	Cytotoxicity against human Hep3B cells after 48 hrs by MTT based ELISA Cytotoxicity against human Hep3B cells after 48 hrs by MTT based ELISA	[PMID: 21504204]
HepG2	IC₅₀	107.51 μM Compound: 1, FTS, S-trans,trans-FTS, Salirasib	Cytotoxicity against human HepG2 cells after 48 hrs by MTT based ELISA Cytotoxicity against human HepG2 cells after 48 hrs by MTT based ELISA	[PMID: 21504204]
HepG2	IC₅₀	48.6 μM Compound: Farnesyl Thiosalicylic acid	Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth by MTT assay Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth by MTT assay	[PMID: 32791404]
MCF7	IC₅₀	46.75 μM Compound: FTA	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 20435479]
MCF7	IC₅₀	48.6 μM Compound: Farnesyl Thiosalicylic acid	Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth by MTT assay Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth by MTT assay	[PMID: 32791404]
MCF7	IC₅₀	49.1 μM Compound: FTS	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 24300920]
MDA-MB-231	IC₅₀	51.22 μM Compound: FTA	Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 20435479]
MEF	IC₅₀	14.3 μM Compound: FTS	Cytotoxicity against icmt-double mutant MEF cells after 5 days by MTT assay Cytotoxicity against icmt-double mutant MEF cells after 5 days by MTT assay	[PMID: 22754607]
MEF	IC₅₀	15.3 μM Compound: FTS	Cytotoxicity against icmt-positive MEF cells after 5 days by MTT assay Cytotoxicity against icmt-positive MEF cells after 5 days by MTT assay	[PMID: 22754607]
MIA PaCa-2	EC₅₀	>20 μM Compound: FTS, Salirasib	Cytotoxicity against human MIAPaCa2 cells harboring K-Ras mutant oncogene after 48 hrs by fluorescence assay Cytotoxicity against human MIAPaCa2 cells harboring K-Ras mutant oncogene after 48 hrs by fluorescence assay	[PMID: 24852279]
NCI-H1299	GI₅₀	85 μM Compound: 12	Antiproliferative activity against human H1299 cells assessed as inhibition of culture growth incubated for 48 hrs by SRB assay Antiproliferative activity against human H1299 cells assessed as inhibition of culture growth incubated for 48 hrs by SRB assay	[PMID: 37531922]
NCI-H460	IC₅₀	48.6 μM Compound: Farnesyl Thiosalicylic acid	Cytotoxicity against human NCI-H460 cells assessed as inhibition of cell growth by MTT assay Cytotoxicity against human NCI-H460 cells assessed as inhibition of cell growth by MTT assay	[PMID: 32791404]
NCI-H460	IC₅₀	49.2 μM Compound: FTS	Cytotoxicity against human H460 cells after 48 hrs by MTT assay Cytotoxicity against human H460 cells after 48 hrs by MTT assay	[PMID: 24300920]
PANC-1	IC₅₀	35 μM Compound: FTS	Cytotoxicity against human PANC1 cells after 5 to 7 days Cytotoxicity against human PANC1 cells after 5 to 7 days	[PMID: 19072665]
PANC-1	IC₅₀	35.2 μM Compound: Salirasib	Antiproliferative activity against human PANC-1 cells assessed as cell growth inhibition Antiproliferative activity against human PANC-1 cells assessed as cell growth inhibition	[PMID: 33228976]
PANC-1	IC₅₀	53.6 μM Compound: FTS	Cytotoxicity against human PANC1 cells after 48 hrs by MTT assay Cytotoxicity against human PANC1 cells after 48 hrs by MTT assay	[PMID: 24300920]
Rat1	EC₅₀	7.5 μM Compound: Salirasib	Inhibition of cell growth in rat Rat1 cells transfected with HRAS Inhibition of cell growth in rat Rat1 cells transfected with HRAS	[PMID: 33228976]
SGC-7901	IC₅₀	37.74 μM Compound: FTA	Cytotoxicity against human SGC7901 cells after 48 hrs by MTT assay Cytotoxicity against human SGC7901 cells after 48 hrs by MTT assay	[PMID: 20435479]
SGC-7901	IC₅₀	41.3 μM Compound: FTS	Cytotoxicity against human SGC7901 cells after 48 hrs by MTT assay Cytotoxicity against human SGC7901 cells after 48 hrs by MTT assay	[PMID: 24300920]
SK-OV-3	IC₅₀	51.2 μM Compound: FTS	Cytotoxicity against human SKOV3 cells after 48 hrs by MTT assay Cytotoxicity against human SKOV3 cells after 48 hrs by MTT assay	[PMID: 24300920]
SMMC-7721	IC₅₀	48.6 μM Compound: Farnesyl Thiosalicylic acid	Cytotoxicity against human SMMC-7721 cells assessed as inhibition of cell growth by MTT assay Cytotoxicity against human SMMC-7721 cells assessed as inhibition of cell growth by MTT assay	[PMID: 32791404]
SMMC-7721	IC₅₀	6.7 μM Compound: FTS	Cytotoxicity against human SMMC-7721 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay Cytotoxicity against human SMMC-7721 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay	[PMID: 33143937]
SMMC-7721	IC₅₀	69.7 μM Compound: FTS	Cytotoxicity against human SMMC7721 cells after 48 hrs by MTT assay Cytotoxicity against human SMMC7721 cells after 48 hrs by MTT assay	[PMID: 24300920]
SMMC-7721	IC₅₀	71.22 μM Compound: 1, FTS, S-trans,trans-FTS, Salirasib	Cytotoxicity against human SMMC7721 cells after 48 hrs by MTT based ELISA Cytotoxicity against human SMMC7721 cells after 48 hrs by MTT based ELISA	[PMID: 21504204]
SW1573	GI₅₀	41 μM Compound: 12	Antiproliferative activity against human SW1573 cells assessed as inhibition of culture growth incubated for 48 hrs by SRB assay Antiproliferative activity against human SW1573 cells assessed as inhibition of culture growth incubated for 48 hrs by SRB assay	[PMID: 37531922]
T47D	GI₅₀	42 μM Compound: 12	Antiproliferative activity against human T47D cells assessed as inhibition of culture growth incubated for 48 hrs by SRB assay Antiproliferative activity against human T47D cells assessed as inhibition of culture growth incubated for 48 hrs by SRB assay	[PMID: 37531922]
U-251	IC₅₀	46.91 μM Compound: FTA	Cytotoxicity against human U251 cells after 48 hrs by MTT assay Cytotoxicity against human U251 cells after 48 hrs by MTT assay	[PMID: 20435479]
U-87MG ATCC	IC₅₀	50 μM Compound: FTS	Cytotoxicity against human U87 cells after 5 to 7 days Cytotoxicity against human U87 cells after 5 to 7 days	[PMID: 19072665]
U-87MG ATCC	IC₅₀	53.95 μM Compound: FTA	Cytotoxicity against human U87 cells after 48 hrs by MTT assay Cytotoxicity against human U87 cells after 48 hrs by MTT assay	[PMID: 20435479]
Vero	IC₅₀	210 μM Compound: 1j	Cytotoxicity against African green monkey Vero cells after 72 hrs by MTT assay Cytotoxicity against African green monkey Vero cells after 72 hrs by MTT assay	[PMID: 31803400]

In Vitro

Salirasib (12.5-100 μM) inhibits the proliferation of ELT3 cells in a dose-dependent manner with an average IC₅₀ of 58.57±4.59 μM. The effects of Salirasib on the TSC2-null cells are evidently mimicked by DN-Rheb but not by DN-Ras. Salirasib reduces Rheb in TSC2-null cells and TSC2 expression rescues the cells from the inhibitory effect of Salirasib. Salirasib reduces phosphorylation of S6K but not of ERK in the TSC2-null ELT3 cells^[1]. Salirasib (50, 100, 150 μM) induces a dose- and time-dependent decrease of cell growth in HCC cells. Salirasib reduces cell proliferation through modulation of cell cycle effectors and inhibitors. Salirasib induces apoptosis in HepG2 and Hep3B cells. The growth inhibitory effect of salirasib in HCC cell lines is associated with mTOR inhibition independent of ERK or Akt activation^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.

In Vivo

Salirasib (40, 60 or 80 mg/kg, p.o.) significantly inhibits the tumor growth in a dose dependent manner in vivo^[1]. Salirasib (5 mg/kg, i.p.) significantly decreases Ras expression in the dy^2J/dy^2Jmice, and causes an increase in Ras expression which is by far much lower than the increase observed in the dy^2J/dy^2J mice. Salirasib treatment is associated with significantly inhibition of both MMP-2 and MMP-9 activities in the dy^2J/dy^2J mice^[2]. Salirasib (10 mg/kg, i.p.) inhibits tumour growth in a subcutaneous xenograft mice model without weight loss^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 162520-00-5
Appearance Solid
Molecular Weight 358.54
Formula C₂₂H₃₀O₂S
Color White to light yellow
SMILES

O=C(O)C1=CC=CC=C1SC/C=C(C)/CC/C=C(C)/CC/C=C(C)/C
Synonyms

S-Farnesylthiosalicylic acid; Farnesyl Thiosalicylic Acid; FTS
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (16)

All WBRT-PCRIFHistological Imaging/Staining

Sort by:

Journal Impact Factor

Adv Sci (Weinh)

PADI2-Catalyzed MEK1 Citrullination Activates ERK1/2 and Promotes IGF2BP1-Mediated SOX2 mRNA Stability in Endometrial Cancer. [Abstract]

2021 Jan 29;8(6):2002831. PMID: 33747724

Salirasib purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2021 Jan 29;8(6):2002831. [Abstract]

Salirasib (50 μM) decreased the protein expression of p-MEK1 in HEK293 cells overexpressed with PADI2 (WT or C647S).
Cell Death Dis

UBIAD1 suppresses the proliferation of bladder carcinoma cells by regulating H-Ras intracellular trafficking via interaction with the C-terminal domain of H-Ras. [Abstract]

2018 Dec 5;9(12):1170. PMID: 30518913

Salirasib purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2018 Dec 5;9(12):1170. [Abstract]

Salirasib (35 μM; 72 h) prevented ERK phosphorylation in the absence of UBIAD1 in HEK293T cells.
Free Radic Biol Med

Modulation of glutamate metabolic reprogramming via Ras-Raf-MEK/ERK signaling alleviates immune inflammation of astrocytes in glaucomatous neurodegeneration. [Abstract]

2026 Apr:247:469-485. PMID: 41692317

Salirasib purchased from MedChemExpress. Usage Cited in: Free Radic Biol Med. 2026 Apr:247:469-485. [Abstract]

Salirasib (FTS; 50 μM; 72 h) increased LPS-induced c-Raf, p-ERK, p-MEK, Ras protein expression in primary astrocytes.

Salirasib purchased from MedChemExpress. Usage Cited in: Free Radic Biol Med. 2026 Apr:247:469-485. [Abstract]

Salirasib (FTS; 50 μM; 72 h) rescued the LPS-induced downregulation of EAAT1, EAAT2, and GS in primary astrocytes and C8-D1A cells.

Salirasib purchased from MedChemExpress. Usage Cited in: Free Radic Biol Med. 2026 Apr:247:469-485. [Abstract]

Salirasib (FTS; 50 μM; 72 h) rescued the LPS-induced upregulation of GFAP, IL-1β, IL-6, and TNF-α mRNA levels (RT-qPCR) in primary astrocytes.

Salirasib purchased from MedChemExpress. Usage Cited in: Free Radic Biol Med. 2026 Apr:247:469-485. [Abstract]

Salirasib (FTS; 5 mg/kg; i.p.; daily for 28 days) significantly downregulated the expression of Ras, c-Raf, MEK, ERK, and abnormally phosphorylated MEK and ERK proteins in the retinas of C57BL/6J mice with EAG model.

Salirasib purchased from MedChemExpress. Usage Cited in: Free Radic Biol Med. 2026 Apr:247:469-485. [Abstract]

Salirasib (FTS; 5 mg/kg; i.p.; daily for 28 days) prevented RGC loss by immunolabeling for Brn3a in C57BL/6J mice with EAG model.

Salirasib purchased from MedChemExpress. Usage Cited in: Free Radic Biol Med. 2026 Apr:247:469-485. [Abstract]

Salirasib (FTS; 5 mg/kg; i.p.; daily for 28 days) observed an increased number of cells in the ganglion cell layer, neatly arranged cells in the optic nerves, and preservation of myelin integrity in the optic nerves in C57BL/6J mice with EAG model.
Clin Transl Med

Targeting c-Myc enhances immunotherapy efficacy in combination with Ras inhibitor in triple-negative breast cancer. [Abstract]

2025 Oct;15(10):e70484. PMID: 41020311
Life Sci

Low GPR81 in ER+ breast cancer cells drives tamoxifen resistance through inducing PPARα-mediated fatty acid oxidation. [Abstract]

2024 Aug 1:350:122763. PMID: 38823505
Life Sci

Talin1 regulates endometrial adhesive capacity through the Ras signaling pathway. [Abstract]

2021 Jun 1:274:119332. PMID: 33711384
Int J Pharm

Solanesol derived therapeutic carriers for anticancer drug delivery. [Abstract]

2019 Dec 15:572:118823. PMID: 31715346
Int J Mol Sci

Neutrophil Extracellular Trap Formation Model Induced by Monosodium Urate and Phorbol Myristate Acetate: Involvement in MAPK Signaling Pathways. [Abstract]

2024 Dec 27;26(1):143. PMID: 39796001
ACS Appl Bio Mater

Mediated Imaging and Improved Targeting of Farnesylthiosalicylic Acid Delivery for Pancreatic Cancer via Conjugation with Near-Infrared Fluorescence Heptamethine Carbocyanine Dye. [Abstract]

2020 Feb 17;3(2):1129-1138. PMID: 35019314
Neoplasia

STAMBP promotes lung adenocarcinoma metastasis by regulating the EGFR/MAPK signaling pathway. [Abstract]

2021 Jun;23(6):607-623. PMID: 34102455
Lab Invest

Upregulation of KLHL17 promotes the proliferation and migration of non-small cell lung cancer by activating the Ras/MAPK signaling pathway. [Abstract]

2022 Dec;102(12):1389-1399. PMID: 35978057
Cytokine

TGF-beta inhibitors influence leishmania infection outcome in a susceptible host. [Abstract]

2026 Aug:204:157169. PMID: 42143915
Discov Oncol

Syndecan-4 promotes gastric cancer progression through activating TGF-β1 induced lipid reprogramming and contributes positive loop circuits. [Abstract]

2025 Jun 14;16(1):1104. PMID: 40516011
Epilepsy Res

Vitamin D3 prevents epileptic seizures by modulating the ras signalling pathway via Gnb1 and Casr in acute epilepsy mouse models. [Abstract]

2026 May 14:225:107820. PMID: 42150281
bioRxiv

2025 Oct 25.
Research Square Preprint

2024 Dec 25.

Solvent & Solubility

In Vitro:

DMSO : ≥ 50 mg/mL (139.45 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.7891 mL

13.9454 mL

27.8909 mL

5 mM

0.5578 mL

2.7891 mL

5.5782 mL

10 mM

0.2789 mL

1.3945 mL

2.7891 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (6.97 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: 2.5 mg/mL (6.97 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (6.97 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protocols

All Animals and Diseases

Patient-Derived Xenograft (PDX)
Patient-derived xenograft (PDX) models are generated by engrafting primary human tumor tissue directly into immunodeficient mice, allowing in vivo propagation of patient tumor biology without initial in vitro adaptation. These models are used to preserve key histopathological and molecular characteristics of the original tumor and enable assessment of tumor growth dynamics and therapeutic response in a living organism. The biological readout is tumor engraftment and subsequent growth in the murine host, which reflects the ability of human tumor cells to survive, vascularize, and expand in an immunocompromised microenvironment.
Patient-Derived Orthotopic Xenograft (PDOX)
Patient-derived orthotopic xenograft (PDOX) modeling implants fresh patient tumor tissue or patient-derived tumor cells into the anatomically corresponding organ or tissue site of immunodeficient mice, usually by surgical orthotopic implantation, to preserve patient tumor histology, local microenvironmental context, invasion, metastatic behavior, and treatment-response features better than subcutaneous implantation. PDOX readouts include tumor engraftment, orthotopic tumor growth, local invasion, metastasis, recurrence after resection, histologic similarity to the donor tumor, biomarker retention, molecular concordance, survival, and response or resistance to therapy. PDOX models are used for preclinical drug testing and individualized therapy evaluation, but engraftment success varies by tumor type and specimen quality.
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
Orthotopic Cell-Line Xenograft
Orthotopic cell-line xenograft models involve implantation of human cancer cell lines into the anatomically corresponding organ of immunodeficient mice to reproduce tumor growth within a native microenvironment, enabling more clinically relevant tumor behavior compared with subcutaneous models. These models are widely used because orthotopic placement better recapitulates tumor progression, including invasion and metastatic spread, which are often underrepresented in heterotopic implantation systems. Compared with conventional xenografts, orthotopic implantation is described as more technically complex but provides improved simulation of tumor-microenvironment interactions and metastatic behavior, making it particularly valuable for translational oncology research. Surgical orthotopic implantation approaches have been emphasized as enabling faithful reproduction of clinical cancer features, including metastasis and disease progression patterns that align with the tumor’s organ of origi

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (276 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Makovski V, et al. Farnesylthiosalicylic acid (salirasib) inhibits Rheb in TSC2-null ELT3 cells: a potential treatment for lymphangioleiomyomatosis. Int J Cancer. 2012 Mar 15;130(6):1420-9. [Content Brief]

[2]. Nevo Y, et al. Chapman J. The Ras antagonist, farnesylthiosalicylic acid (FTS), decreases fibrosis and improves muscle strength in dy/dy mouse model of muscular dystrophy. PLoS One. 2011 Mar 22;6(3):e18049. [Content Brief]

[3]. Charette N, et al. Salirasib inhibits the growth of hepatocarcinoma cell lines in vitro and tumor growth in vivo through ras and mTOR inhibition. Mol Cancer. 2010 Sep 22;9:256. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.7891 mL	13.9454 mL	27.8909 mL	69.7272 mL
	5 mM	0.5578 mL	2.7891 mL	5.5782 mL	13.9454 mL
	10 mM	0.2789 mL	1.3945 mL	2.7891 mL	6.9727 mL
	15 mM	0.1859 mL	0.9297 mL	1.8594 mL	4.6485 mL
	20 mM	0.1395 mL	0.6973 mL	1.3945 mL	3.4864 mL
	25 mM	0.1116 mL	0.5578 mL	1.1156 mL	2.7891 mL
	30 mM	0.0930 mL	0.4648 mL	0.9297 mL	2.3242 mL
	40 mM	0.0697 mL	0.3486 mL	0.6973 mL	1.7432 mL
	50 mM	0.0558 mL	0.2789 mL	0.5578 mL	1.3945 mL
	60 mM	0.0465 mL	0.2324 mL	0.4648 mL	1.1621 mL
	80 mM	0.0349 mL	0.1743 mL	0.3486 mL	0.8716 mL
	100 mM	0.0279 mL	0.1395 mL	0.2789 mL	0.6973 mL

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Salirasib

Publications Citing Use of MedChemExpress (MCE) Salirasib

All Ras Isoforms